News

Immunotherapy Could Improve Duchenne Muscular Dystrophy Outcomes

New research out of Germany indicates that immune therapy might help treat Duchenne muscular dystrophy (DMD), a serious disease that causes muscle weakness. In a mouse model of the disease, the ability to run, as well as disease biomarkers, appeared to improve following antibody treatment, specifically a form of human…

Critical Path Institute Forms 10th Consortium for Duchenne Muscular Dystrophy

Arizona-based Critical Path Institute (C-Path), a leading non-profit organization committed to accelerate and reduce developmental costs of medical products, recently announced it has formed its 10th consortium: The Duchenne Regulatory Sciences Consortium (D-RSC). Together with Parent Project Muscular Dystrophy (PPMD), the new consortium will utilize C-Path’s tested consensus science model to find a cure for…

Parent Project Muscular Dystrophy Awards $70,000 To Talem Technologies

Parent Project Muscular Dystrophy (PPMD), a nonprofit organization on the front line against Duchenne muscular dystrophy (Duchenne), has recently announced it awarded Talem Technologies a $70,000 grant to support a pilot study concerning their X-Ar exoskeletal arm technology. This follows PPMD’s launch of their Robotics Initiative that serves to explore devices that have the potential to…

Santhera Doses First CMD Patient with Omigapil, Completes CALLISTO Clinical Trial Enrolment

Santhera Pharmaceuticals, a Swiss pharmaceutical company specialized in developing and commercializing breakthrough treatments for orphan mitochondrial and neuromuscular diseases, announced that it has dosed the first patient in its CALLISTO Phase I trial that aims to evaluate the safety and tolerability profile of orally-stable omigapil for Congenital Muscular Dystrophy (CMD). All necessary participants have…